Universe Pharmaceuticals annual ebitda margin
2019
2020
2021
2022
2023
2024
2025
Universe Pharmaceuticals's ebitda margin was −13.43% for fiscal 2025.
View full Universe Pharmaceuticals company overview| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-09-30 | −13.43% | +19.29 pp |
| 2024 | 2024-09-30 | −32.72% | −22.02 pp |
| 2023 | 2023-09-30 | −10.70% | +5.46 pp |
| 2022 | 2022-09-30 | −16.16% | −45.41 pp |
| 2021 | 2021-09-30 | 29.25% | −5.47 pp |
| 2020 | 2020-09-30 | 34.72% | +4.12 pp |
| 2019 | 2019-09-30 | 30.61% | — |
Over the last five fiscal years, Universe Pharmaceuticals's ebitda margin decreased from 34.72% to −13.43%, a change of −48.15 percentage points.
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Universe Pharmaceuticals source filings ↗